Future cardiology · 2025
Efficacy and safety of transcatheter aortic valves in patients with aortic stenosis: a network meta-analysis.
СтатьяNetwork Meta-AnalysisНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Adnan Maryam, Ahmed Usman Muhammad, Akhtar Muzamil, Hameed Hira, Hussain Bakhtiari Muhammad Irtaza, Hamza Mohammad, Zaheer Warda, Shoaib Iqra, Saleem Aroma, Basit Jawad, Alraies M Chadi
Аннотация
BACKGROUND: Patients with aortic stenosis have a high mortality risk treatable by transcatheter aortic valve replacement (TAVR). We conducted a network meta-analysis to compare the efficacy and safety of transcatheter aortic valves in aortic stenosis patients.
METHODS: A systematic search of PubMed, Embase, and Cochrane was conducted. Randomized controlled trials (RCTs) that included adult patients with aortic stenosis undergoing TAVR, which compared clinical efficacy and safety between any of the transcatheter aortic valves, were included. Random effects meta-analysis was employed.
RESULTS: A total of 4687 patients from 9 RCTs were included. Sapien XT had a significantly higher risk of stroke compared to Sapien 3 RR = 31.38 (95% CI: 1.12 to 876, p = 0.043), while other devices showed no significant differences. Evolut had a significantly increased risk of permanent pacemaker placement compared to Sapien 3 RR = 1.36 (95% CI: 1.07-1.74, p = 0.013). No significant differences were observed between valves for any of the other analyzed outcomes.
CONCLUSION: While most TAVR devices showed comparable safety profiles, Evolut was associated with increased pacemaker implantation risk. The higher stroke risk with Sapien XT should be interpreted with caution.
PROTOCOL REGISTRATION: This review was registered with PROSPERO (CRD42024563628).
METHODS: A systematic search of PubMed, Embase, and Cochrane was conducted. Randomized controlled trials (RCTs) that included adult patients with aortic stenosis undergoing TAVR, which compared clinical efficacy and safety between any of the transcatheter aortic valves, were included. Random effects meta-analysis was employed.
RESULTS: A total of 4687 patients from 9 RCTs were included. Sapien XT had a significantly higher risk of stroke compared to Sapien 3 RR = 31.38 (95% CI: 1.12 to 876, p = 0.043), while other devices showed no significant differences. Evolut had a significantly increased risk of permanent pacemaker placement compared to Sapien 3 RR = 1.36 (95% CI: 1.07-1.74, p = 0.013). No significant differences were observed between valves for any of the other analyzed outcomes.
CONCLUSION: While most TAVR devices showed comparable safety profiles, Evolut was associated with increased pacemaker implantation risk. The higher stroke risk with Sapien XT should be interpreted with caution.
PROTOCOL REGISTRATION: This review was registered with PROSPERO (CRD42024563628).